PL3761955T3 - Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów - Google Patents
Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworówInfo
- Publication number
- PL3761955T3 PL3761955T3 PL19724635.8T PL19724635T PL3761955T3 PL 3761955 T3 PL3761955 T3 PL 3761955T3 PL 19724635 T PL19724635 T PL 19724635T PL 3761955 T3 PL3761955 T3 PL 3761955T3
- Authority
- PL
- Poland
- Prior art keywords
- tumours
- polysaccharide
- treatment
- anthracycline encapsulated
- anthracycline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL424773A PL424773A1 (pl) | 2018-03-06 | 2018-03-06 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
| PCT/PL2019/050014 WO2019172790A1 (en) | 2018-03-06 | 2019-03-05 | Anthracycline encapsulated with polysaccharide for use in the treatment of tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3761955T3 true PL3761955T3 (pl) | 2025-12-22 |
Family
ID=66554462
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL424773A PL424773A1 (pl) | 2018-03-06 | 2018-03-06 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
| PL19724635.8T PL3761955T3 (pl) | 2018-03-06 | 2019-03-05 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL424773A PL424773A1 (pl) | 2018-03-06 | 2018-03-06 | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210052616A1 (pl) |
| EP (1) | EP3761955B1 (pl) |
| KR (1) | KR102860522B1 (pl) |
| CN (1) | CN112165933B (pl) |
| ES (1) | ES3052184T3 (pl) |
| PL (2) | PL424773A1 (pl) |
| WO (1) | WO2019172790A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102300362B1 (ko) * | 2019-10-08 | 2021-09-08 | 고려대학교 산학협력단 | 간세포성 암종 특이적 항암 치료진단제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2550261B2 (ja) * | 1992-05-20 | 1996-11-06 | 株式会社ディ・ディ・エス研究所 | 酸化カルボキシメチルマンノグルカンードキソルビシン複合体 |
| EP1898881B1 (en) * | 2005-05-27 | 2012-04-04 | Royer Biomedical, INC. | Bioresorbable polymer matrices and methods of making and using the same |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| US20110104052A1 (en) * | 2007-12-03 | 2011-05-05 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| CN101653612A (zh) * | 2009-07-23 | 2010-02-24 | 复旦大学 | 利用白蛋白-葡聚糖制备的阿霉素纳米制剂及其应用 |
| EP2611424B1 (en) * | 2010-08-31 | 2024-04-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Crosslinked polysaccharide beads and their biomedical uses |
| PL221351B1 (pl) * | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
| CN104523598B (zh) * | 2014-12-16 | 2017-11-14 | 中国科学院长春应用化学研究所 | 葡聚糖/阿霉素键合药纳米粒及其制备方法 |
| KR101842059B1 (ko) * | 2016-02-05 | 2018-03-26 | 인하대학교 산학협력단 | 음이온성 작용기 및 아크릴레이트기가 도입된 광가교성 덱스트란 고분자 약물전달체 및 이의 제조방법 |
| CN105727309B (zh) * | 2016-03-31 | 2019-04-30 | 中国药科大学 | 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用 |
-
2018
- 2018-03-06 PL PL424773A patent/PL424773A1/pl unknown
-
2019
- 2019-03-05 CN CN201980017745.XA patent/CN112165933B/zh active Active
- 2019-03-05 WO PCT/PL2019/050014 patent/WO2019172790A1/en not_active Ceased
- 2019-03-05 KR KR1020207027492A patent/KR102860522B1/ko active Active
- 2019-03-05 US US16/978,476 patent/US20210052616A1/en not_active Abandoned
- 2019-03-05 PL PL19724635.8T patent/PL3761955T3/pl unknown
- 2019-03-05 EP EP19724635.8A patent/EP3761955B1/en active Active
- 2019-03-05 ES ES19724635T patent/ES3052184T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3761955A1 (en) | 2021-01-13 |
| KR102860522B1 (ko) | 2025-09-16 |
| PL424773A1 (pl) | 2019-09-09 |
| WO2019172790A1 (en) | 2019-09-12 |
| KR20200128694A (ko) | 2020-11-16 |
| CN112165933A (zh) | 2021-01-01 |
| US20210052616A1 (en) | 2021-02-25 |
| EP3761955B1 (en) | 2025-10-08 |
| EP3761955C0 (en) | 2025-10-08 |
| CN112165933B (zh) | 2024-04-16 |
| ES3052184T3 (en) | 2026-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2564383B (en) | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex | |
| GB201719076D0 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
| EP3134115A4 (en) | Methods and compositions for treating metastatic breast cancer and other cancers in the brain | |
| PL3624837T3 (pl) | Przeciwciała anty-fgfr2 w połączeniu ze środkami chemioterapeutycznymi w leczeniu nowotworu | |
| EP3250609A4 (en) | Il13ra alpha 2 binding agents and use thereof in cancer treatment | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| IL280510B1 (en) | Antibody-drug conjugates for use in the treatment of metastatic brain tumors | |
| EP3242688A4 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
| EP3151829A4 (en) | Novel sesquiterpene derivatives and their use in inflammation and cancer treatment | |
| IL273470A (en) | Semaglutide in medical treatment | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| IL290251A (en) | Combination for effective treatment of metastatic cancer in patients | |
| GB201820659D0 (en) | Novel compostions and their use in therapy | |
| ZA201804361B (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| IL259510A (en) | 1, 3, 4-thiadiazole compounds and their use for cancer treatment | |
| PL3253208T3 (pl) | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi | |
| ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| IL258644A (en) | 4,3,1-thiadiazole compounds and their use for cancer treatment | |
| SG11202007005UA (en) | Use of crassocephalum rabens extract in the treatment of breast cancer | |
| PL3630112T3 (pl) | Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu | |
| PL3761955T3 (pl) | Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| SG11202105276TA (en) | Oligo-benzamide analogs and their use in cancer treatment | |
| IL259205B (en) | Glycolipid compounds and their uses in the treatment of tumors |